Loading...
•
Aug 31, 2023
AngioDynamics Q1 2024 Earnings Report
AngioDynamics reported strong performance across both businesses, driven by NanoKnife and international markets in Q1 2024
Key Takeaways
AngioDynamics reported net sales of $78.7 million. GAAP earnings per share was $1.15, while adjusted loss per share was $0.12. The company reaffirmed its fiscal year 2024 guidance.
Net sales of $78.7 million as reported.
Med Tech net sales of $25.9 million increased 13.3%.
GAAP earnings per share of $1.15.
Cash and cash equivalents at August 31, 2023 were $57.6 million.
AngioDynamics
AngioDynamics
AngioDynamics Revenue by Segment
AngioDynamics Revenue by Geographic Location
Revenue by Segment
Med Tech Revenue
CapyFin.comMed Device Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
The Company continues to expect its fiscal year 2024 net sales to be in the range of $328 to $333 million, gross margin to be approximately 50% to 52% and adjusted loss per share in the range of $0.28 to $0.34.
Positive Outlook
- Net sales to be in the range of $328 to $333 million
- Gross margin to be approximately 50% to 52%
Challenges Ahead
- Adjusted loss per share in the range of $0.28 to $0.34
Revenue & Expenses
Visualization of income flow from segment revenue to net income